The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation.

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are overprescribing them and some patients are taking them in secret.

The US Food and Drug Administration (FDA) has instructed all GLP-1 drug-makers to update their warning labels to include the ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related ...

Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer ...

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six ...

People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, ...

A study from Florida State University uncovers biological and behavioral consequences of weight loss underlying binge-eating ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

With the sales of weight-loss drugs booming, India is now the epicentre of the global obesity treatment market, reports The ...